Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Open in API
Filings indexed 576 across all filing types
Latest filing 2021-06-18 Director's Dealing
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-06-18 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2021, reporting the results of operations for the quarter ended March 31, 2021. It references a press release attached as Exhibit 99.1 that sets forth the company's financial results. The text explicitly states that the information is being furnished under Item 2.02 (Results of Operations and Financial Condition) and that the press release is incorporated by reference. The document itself is a current report (8-K) and not a full quarterly or annual report. The length is 3631 characters, which is relatively short and consistent with an 8-K filing announcing earnings results. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Therefore, the correct classification is ER with high confidence.
2021-05-11 English
Director's Dealing 2021
Director's Dealing
2021-05-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive additional proxy statement material related to the Annual Meeting of Stockholders. It includes details about the meeting date, proposals to elect directors, and ratify the appointment of the independent auditor. It is not the proxy statement itself but additional materials related to it. This type of document is classified under Proxy Solicitation & Information Statement (PSI) filings, which cover materials sent to shareholders to provide information and request votes for meetings. The document length is 4777 characters, which is consistent with a proxy solicitation material rather than a full annual report or other filings. Therefore, the correct classification is PSI with high confidence.
2021-04-30 English
DEF 14A
Proxy Solicitation & Information Statement
2021-04-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.